Just a little over a year after it emerged from stealth mode, the company - which recently initiated a clinical trial of a drug targeting allosteric mutations in solid tumors - has filed to go public.
The company is targeting pathways such as SHP2 and KRAS G12C. RAS mutations have been an attractive target in oncology due to the central role they play in cancers.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
The company has raised more than $100 million since 2017 and plans to use the current funding to build a pipeline of RNA-targeting small molecules.
The raise comes a month after the Cambridge, Massachusetts-based firm's launch with a $20 million Series A round. Black Diamond is developing drugs that target allosteric mutant oncogenes, which it describes as an unexplored space.